The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis
Maria Vernucci(Institute for Experimental Endocrinology and Oncology), Andrea Riccio(University of Campania "Luigi Vanvitelli"), Paolo V. Pedone(University of Rome Tor Vergata), Carmelo B. Bruni(Institute for Experimental Endocrinology and Oncology), Nathalie Besnard(Institute for Experimental Endocrinology and Oncology), Flavia Cerrato(University of Campania "Luigi Vanvitelli"), Stefano Casola(IFOM)
Cited by 35
Related Papers
Regulation of the Germinal Center Response by MicroRNA-155
|Science|2007|1.5k
Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination
|Nature Immunology|2006|771
Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement
|Nature Reviews Endocrinology|2018|596
B cell receptor signal strength determines B cell fate
|Nature Immunology|2004|556
Genomic imprinting disorders: lessons on how genome, epigenome and environment interact
|Nature Reviews Genetics|2019|462